Equazen ® Reaffirms Its Commitment to Uncompromising Quality and Sustainability in Omegas Supplements
26.6.2025 08:00:00 CEST | Business Wire | Press Release
SFI Health™EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, highlights today its ongoing commitment to delivering the highest standard of quality for Equazen®, the company’s global science-based food supplement brand designed to nourish, enhance and support the brain’s potential.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625554235/en/
Equazen® continues to set the benchmark for excellence at every step of the value chain
At SFI Health™, quality is more than a requirement—it is a mission. The company is committed to enhancing people’s well-being by developing natural supplements that combine passion for nature-based healthcare, science, state-of-the-art production standards and sustainability, from ingredient sourcing to the final product reaching the patient.
In particular, with over 25 years of trust built across multiple markets, Equazen®'s excellence is built on five core pillars:
- Ingredients Sourcing: Equazen®’s story begins in the sea, with responsibly sourced fish oil rich in essential Omega-3 fatty acids EPA and DHA, paired with cold-pressed evening primrose and borage seeds oils for Omega-6 (GLA). Every ingredient is carefully selected from certified suppliers, processed using validated methods ensuring purity and safety as well as full traceability in compliance with European Pharmacopoeia regulations. Besides, Equazen® suppliers are part of the IFFO, the international marine ingredients organization, promoting responsible sourcing and high-quality manufacturing in the industry of fish oil.
- Manufacturing & Supply Chain: Equazen® is produced under strict GMP standards, with each fish oil batch undergoing rigorous quality testing. All manufacturers adhere to recognized food safety systems, including HACCP and FDA registration. The supply chain is equally controlled—from packaging to transport—to protect product integrity till it reaches consumers. In addition, Equazen®’s suppliers are members of GOED (Global Organization for EPA and DHA Omega-3s), a respected international association setting high ethical and quality standards for the Omega-3 industry.
- Science-backed innovation: Equazen® products feature a unique and carefully balanced combination of essential fatty acids (Omega 3 and Omega 6), designed to support cognitive needs. Since its inception in 1999, Equazen® products’ benefits for the human brain have been proven in over 15 pre-clinical and clinical investigations. In addition, ongoing collaborations with global experts and research institutions further strengthen the scientific foundation.
- Customer focus: Understanding and responding to consumer needs is key to Equazen®’s success. Feedback from parents, healthcare professionals, and consumers shapes product development and ongoing support. The brand also offers personalized guidance and educational resources to optimize usage.
- Sustainability: Equazen® also prioritizes environmental responsibility with sustainable production processes designed to minimize environmental impact. Its fish oil is sourced from regulated, sustainable fisheries and is a by-product of the fishmeal industry—ensuring no additional fish are caught for production. In addition, Equazen® fish oils are certified by Friends of the Sea®, a globally recognized independent body guaranteeing responsible sourcing, full traceability, and environmental stewardship.
“Our mission with Equazen® is to provide natural supplements that parents and caregivers can trust to support cognitive needs and the health of human brain,” said Matthew Brabazon, General Manager at SFI Health™ EMEA. “This is made possible only through ethical sourcing, advanced manufacturing, and robust scientific validation.”
As market demands evolve, Equazen® remains dedicated to pushing quality standards further at every step of the value chain to offer best-in-class solutions for optimal cognitive health. Consumers can trust that every product reflects a passion for health, innovation, and sustainability.
About SFI Health™
SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.
Guided by the belief in the healing potential of natural products, SFI Health™ combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.
An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.
SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.
For more information, go to sfihealth.com or follow us SFI Health on LinkedIn.
About Equazen®
Equazen® is a science-based globally branded food supplement designed and studied to help nourish, enhance, and support the human brain’s potential across all life stages.
Each product of the Equazen® range contains a balanced unique combination of essential fatty acids (Omega-3 and Omega-6), which has been clinically proven for more than 20 years to assist with learning capabilities, concentration and healthy brain development.
Equazen® is available in multiple pharmaceutical formats and sizes to support optimal cognitive functions from infants to teenagers.
Currently marketed in 30 countries globally, Equazen® is widely recommended by healthcare professionals and trusted by families for the last 25 years.
Equazen® aims to advance human health naturally, delivering expertly formulated products that empower individuals to reach their cognitive potential.
For more info visit www.equazen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250625554235/en/
Contacts
For more information
SFI Health™ EMEA Contact
Elisabetta Bianchi
e-mail address: elisabetta.bianchi@sfihealth.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom